

South Korean medical Al firm to assist COVID-19 screening and diagnosis in Indonesia

28 January 2021 | News

Lunit INSIGHT CXR', an AI software for detecting chest abnormalities, and INFINITT's latest PACS system, 'INFINITT PACS G7' for more accurate diagnosis of COVID-19



Lunit, a South Korean medical AI software company, on Jan 27, 2021, announced a partnership with a leading PACS provider INFINITT Healthcare to accelerate its global expansion.

Lunit and INFINITT Healthcare recently entered into a global software distribution and licensing partnership. Implemented in the INFINITT PACS system, Lunit AI will be distributed in the global market and expand its market presence. INFINITT Healthcare is a dominant player in the South Korean PACS market, globally recognized for its technology.

As the first step, the two companies signed their first commercial sales contract with Leuwiliang General Hospital inIndonesia . Leuwiliang General Hospital is one of the leading healthcare institutions of West Java Indonesia that provide diagnosis and treatment of COVID-19 patients.

Radiologists of Leuwiliang General Hospital will use 'Lunit INSIGHT CXR', an AI software for detecting chest abnormalities, and INFINITT's latest PACS system, 'INFINITT PACS G7' for more accurate diagnosis of COVID-19. A recent study published in a peer-reviewed journal 'Plos One' indicated that when using Lunit INSIGHT CXR for COVID-19 screening, it can detect the symptoms with over 95% of sensitivity.

Dr. Suci Syamsiah Ramdhini, a radiologist at Leuwiliang General Hospital stated, "Thanks to Lunit INSIGHT CXR, abnormal lesions such as pneumonia and cardiomegaly were found clearly in complicated lung cases". Experts say that chest x-rays compress and represent three-dimensional human lungs into a two-dimensional, so there may be lesions that are easily missed by radiologists.

Lunit INSIGHT CXR is now supporting medical professionals to diagnose COVID-19 in more than 10 countries and has an accuracy of 97 to 99% in detecting 10 major chest diseases such as lung nodules and pneumothorax. It is CE marked and clinically available in Europe, Middle East, Latin America, South East Asia, Australia, and New Zealand.

